NIH | National Cancer Institute | NCI Wiki  
Long NameResponse NCI Standard Template
DefinitionThe collection of CDEs used in the Response module.
ContextcaBIG
Protocol Long NameNCI Standard Template Forms
WorkflowDRAFT NEW
TypeCRF
Public ID3870614
Version1.0
Module Long NameModule InstructionsQuestionCDECDE Public IDCDE VersionValue Domain Data TypeValue Domain Unit of MeasureDisplay FormatValid ValueForm Value Meaning TextForm Value Meaning Desc.
Mandatory Response QuestionsThese items must be included when this data is collected for reporting.
Was participant assessed for response during this period?Disease Response Evaluation Period Assessment Indicator38211561.0CHARACTER
NoNoThe non-affirmative response to a question.
UnknownUnknownNot known, not observed, not recorded, or refused.
YesYesThe affirmative response to a question or activity.
Method(s) used to determine response (Select all that apply)Disease Response Evaluation Method Type38555601.0CHARACTER
BiomarkersBiomarkerMeasurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc
Clinical AssessmentClinical Assessment ToolAny one of several evaluation/assessment tools used to ascertain a patient's condition or diagnosis.
CytogeneticsCytogenetic AnalysisTechniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.
ImagingImaging TechniqueAny technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.
ImmunologicalImmunologic TechniqueLaboratory technique involving interaction of antigens with specific antibodies.
Laboratory Test(s)Laboratory ProcedureAny procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.
MolecularMolecular AnalysisTechniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).
PathologyPathologyThe medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural functional changes that result from disease processes. Informally used to mean the result of such an examination.
If Not Evaluable or Not Assessed, provide reasonEvaluation Not Done Reason Specify26086001.0CHARACTER
Response Confirmed DateDisease Response Confirmation Date38555871.0DATEMM/DD/YYYY
If response is relapse or progression, indicate site(s)Disease Response Recurrent Disease Or Progression Confirmation Anatomic Site ICD-0-3 Code38555911.0CHARACTER
C00C00 - LIP (excludes skin of lip C44.0)LIP (excludes skin of lip C44.0)
C00-C14C00-C14 - LIP, ORAL CAVITY AND PHARYNXLIP, ORAL CAVITY AND PHARYNX
C00.0C00.0 - External upper lipExternal upper lip
C00.1C00.1 - External lower lipExternal lower lip
C00.2C00.2 - External lip, NOSExternal lip, NOS
C00.3C00.3 - Mucosa of upper lipMucosa of upper lip
C00.4C00.4 - Mucosa of lower lipMucosa of lower lip
C00.5C00.5 - Mucosa of lip, NOSMucosa of lip, NOS
C00.6C00.6 - Commissure of lipCommissure of lip
C00.8C00.8 - Overlapping lesion of lipOverlapping lesion of lip
C00.9C00.9 - Lip, NOS (excludes skin of lip C44.0)Lip, NOS (excludes skin of lip C44.0)
C01C01 - BASE OF TONGUEBASE OF TONGUE
C01.9C01.9 - Base of tongue, NOSBase of tongue, NOS
C02C02 - OTHER AND UNSPECIFIED PARTS OF TONGUEOTHER AND UNSPECIFIED PARTS OF TONGUE
C02.0C02.0 - Dorsal surface of tongue, NOSDorsal surface of tongue, NOS
C02.1C02.1 - Border of tongueBorder of tongue
C02.2C02.2 - Ventral surface of tongue, NOSVentral surface of tongue, NOS
C02.3C02.3 - Anterior 2/3 of tongue, NOSAnterior 2/3 of tongue, NOS
C02.4C02.4 - Lingual tonsilLingual tonsil
C02.8C02.8 - Overlapping lesion of tongueOverlapping lesion of tongue
C02.9C02.9 - Tongue, NOSTongue, NOS
C03C03 - GUMGUM
C03.0C03.0 - Upper gumUpper gum
C03.1C03.1 - Lower gumLower gum
C03.9C03.9 - Gum, NOSGum, NOS
C04C04 - FLOOR OF MOUTHFLOOR OF MOUTH
C04.0C04.0 - Anterior floor of mouthAnterior floor of mouth
C04.1C04.1 - Lateral floor of mouthLateral floor of mouth
C04.8C04.8 - Overlapping lesion of floor of mouthOverlapping lesion of floor of mouth
C04.9C04.9 - Floor of mouth, NOSFloor of mouth, NOS
C05C05 - PALATEPALATE
C05.0C05.0 - Hard palateHard palate
C05.1C05.1 - Soft palate, NOS (excludes nasopharyngeal surface of soft palate C11.3)Soft palate, NOS (excludes nasopharyngeal surface of soft palate C11.3)
C05.2C05.2 - UvulaUvula
C05.8C05.8 - Overlapping lesion of palate (see note page 45)Overlapping lesion of palate (see note page 45)
C05.9C05.9 - Palate, NOSPalate, NOS
C06C06 - OTHER AND UNSPECIFIED PARTS OF MOUTHOTHER AND UNSPECIFIED PARTS OF MOUTH
C06.0C06.0 - Cheek mucosaCheek mucosa
C06.1C06.1 - Vestibule of mouthVestibule of mouth
C06.2C06.2 - Retromolar areaRetromolar area
C06.8C06.8 - Overlapping lesion of other and unspecified parts of mouthOverlapping lesion of other and unspecified parts of mouth
C06.9C06.9 - Mouth, NOSMouth, NOS
C07C07 - PAROTID GLANDPAROTID GLAND
C07.9C07.9 - Parotid glandParotid gland
C08C08 - OTHER AND UNSPECIFIED MAJOR SALIVARY GLANDSOTHER AND UNSPECIFIED MAJOR SALIVARY GLANDS
C08.0C08.0 - Submandibular glandSubmandibular gland
C08.1C08.1 - Sublingual glandSublingual gland
C08.8C08.8 - Overlapping lesion of major salivary glandsOverlapping lesion of major salivary glands
C08.9C08.9 - Major salivary gland, NOSMajor salivary gland, NOS
C09C09 - TONSILTONSIL
C09.0C09.0 - Tonsillar fossaTonsillar fossa
C09.1C09.1 - Tonsillar pillarTonsillar pillar
C09.8C09.8 - Overlapping lesion of tonsilOverlapping lesion of tonsil
C09.9C09.9 - Tonsil, NOS (excludes lingual tonsil C02.4 and pharyngeal tonsil C11.1)Tonsil, NOS (excludes lingual tonsil C02.4 and pharyngeal tonsil C11.1)
C10C10 - OROPHARYNXOROPHARYNX
C10.0C10.0 - ValleculaVallecula
C10.1C10.1 - Anterior surface of epiglottisAnterior surface of epiglottis
C10.2C10.2 - Lateral wall of oropharynxLateral wall of oropharynx
C10.3C10.3 - Posterior wall of oropharynxPosterior wall of oropharynx
C10.4C10.4 - Branchial cleft (site of neoplasm)Branchial cleft (site of neoplasm)
C10.8C10.8 - Overlapping lesion of oropharynxOverlapping lesion of oropharynx
C10.9C10.9 - Oropharynx, NOSOropharynx, NOS
C11C11 - NASOPHARYNXNASOPHARYNX
C11.0C11.0 - Superior wall of nasopharynxSuperior wall of nasopharynx
C11.1C11.1 - Posterior wall of nasopharynxPosterior wall of nasopharynx
C11.2C11.2 - Lateral wall of nasopharynxLateral wall of nasopharynx
C11.3C11.3 - Anterior wall of nasopharynxAnterior wall of nasopharynx
C11.8C11.8 - Overlapping lesion of nasopharynxOverlapping lesion of nasopharynx
C11.9C11.9 - Nasopharynx, NOSNasopharynx, NOS
C12C12 - PYRIFORM SINUSPYRIFORM SINUS
C12.9C12.9 - Pyriform sinusPyriform sinus
C13C13 - HYPOPHARYNXHYPOPHARYNX
C13.0C13.0 - Postcricoid regionPostcricoid region
C13.1C13.1 - Hypopharyngeal aspect of aryepiglottic foldHypopharyngeal aspect of aryepiglottic fold
C13.2C13.2 - Posterior wall of hypopharynxPosterior wall of hypopharynx
C13.8C13.8 - Overlapping lesion of hypopharynxOverlapping lesion of hypopharynx
C13.9C13.9 - Hypopharynx, NOSHypopharynx, NOS
C14C14 - OTHER AND ILL-DEFINED SITES IN LIP, ORAL CAVITY AND PHARYNXOTHER AND ILL
C14.0C14.0 - Pharynx, NOSPharynx, NOS
C14.2C14.2 - Waldeyer ringWaldeyer ring
C14.8C14.8 - Overlapping lesion of lip, oral cavity and pharynxOverlapping lesion of lip, oral cavity and pharynx
C15C15 - ESOPHAGUSESOPHAGUS
C15-C26C15-C26 - DIGESTIVE ORGANSC26
C15.0C15.0 - Cervical esophagusCervical esophagus
C15.1C15.1 - Thoracic esophagusThoracic esophagus
C15.2C15.2 - Abdominal esophagusAbdominal esophagus
C15.3C15.3 - Upper third of esophagusUpper third of esophagus
C15.4C15.4 - Middle third of esophagusMiddle third of esophagus
C15.5C15.5 - Lower third of esophagusLower third of esophagus
C15.8C15.8 - Overlapping lesion of esophagusOverlapping lesion of esophagus
C15.9C15.9 - Esophagus, NOSEsophagus, NOS
C16C16 - STOMACHSTOMACH
C16.0C16.0 - Cardia, NOS Gastric cardiaCardia, NOS Gastric cardia
C16.1C16.1 - Fundus of stomachFundus of stomach
C16.2C16.2 - Body of stomachBody of stomach
C16.3C16.3 - Gastric antrumGastric antrum
C16.4C16.4 - PylorusPylorus
C16.5C16.5 - Lesser curvature of stomach, NOS (not classifiable to C16.1 to C16.4)Lesser curvature of stomach, NOS (not classifiable to C16.1 to C16.4)
C16.6C16.6 - Greater curvature of stomach, NOS (not classifiable to C16.0 to C16.4)Greater curvature of stomach, NOS (not classifiable to C16.0 to C16.4)
C16.8C16.8 - Overlapping lesion of stomachOverlapping lesion of stomach
C16.9C16.9 - Stomach, NOSStomach, NOS
C17C17 - SMALL INTESTINESMALL INTESTINE
C17.0C17.0 - DuodenumDuodenum
C17.1C17.1 - JejunumJejunum
C17.2C17.2 - Ileum (excludes ileocecal valve C18.0)Ileum (excludes ileocecal valve C18.0)
C17.3C17.3 - Meckel diverticulum (site of neoplasm)Meckel diverticulum (site of neoplasm)
C17.8C17.8 - Overlapping lesion of small intestineOverlapping lesion of small intestine
C17.9C17.9 - Small intestine, NOSSmall intestine, NOS
C18C18 - COLONCOLON
C18.0C18.0 - CecumCecum
C18.1C18.1 - AppendixAppendix
C18.2C18.2 - Ascending colonAscending colon
C18.3C18.3 - Hepatic flexure of colonHepatic flexure of colon
C18.4C18.4 - Transverse colonTransverse colon
C18.5C18.5 - Splenic flexure of colonSplenic flexure of colon
C18.6C18.6 - Descending colonDescending colon
C18.7C18.7 - Sigmoid colonSigmoid colon
C18.8C18.8 - Overlapping lesion of colon (see note page 45)Overlapping lesion of colon (see note page 45)
C18.9C18.9 - Colon, NOSColon, NOS
C19C19 - RECTOSIGMOID JUNCTIONRECTOSIGMOID JUNCTION
C19.9C19.9 - Rectosigmoid junctionRectosigmoid junction
C20C20 - RECTUMRECTUM
C20.9C20.9 - Rectum, NOSRectum, NOS
C21C21 - ANUS AND ANAL CANALANUS AND ANAL CANAL
C21.0C21.0 - Anus, NOS (excludes skin of anus and perianal skin C44.5)Anus, NOS (excludes skin of anus and perianal skin C44.5)
C21.1C21.1 - Anal canalAnal canal
C21.2C21.2 - Cloacogenic zoneCloacogenic zone
C21.8C21.8 - Overlapping lesion of rectum, anus and anal canalOverlapping lesion of rectum, anus and anal canal
C22C22 - LIVER AND INTRAHEPATIC BILE DUCTSLIVER AND INTRAHEPATIC BILE DUCTS
C22.0C22.0 - LiverLiver
C22.1C22.1 - Intrahepatic bile ductIntrahepatic bile duct
C23C23 - GALLBLADDERGALLBLADDER
C23.9C23.9 - GallbladderGallbladder
C24C24 - OTHER AND UNSPECIFIED PARTS OF BILIARY TRACTOTHER AND UNSPECIFIED PARTS OF BILIARY TRACT
C24.0C24.0 - Extrahepatic bile ductExtrahepatic bile duct
C24.1C24.1 - Ampulla of VaterAmpulla of Vater
C24.8C24.8 - Overlapping lesion of biliary tractOverlapping lesion of biliary tract
C24.9C24.9 - Biliary tract, NOSBiliary tract, NOS
C25C25 - PANCREASPANCREAS
C25.0C25.0 - Head of pancreasHead of pancreas
C25.1C25.1 - Body of pancreasBody of pancreas
C25.2C25.2 - Tail of pancreasTail of pancreas
C25.3C25.3 - Pancreatic ductPancreatic duct
C25.4C25.4 - Islets of LangerhansIslets of Langerhans
C25.7C25.7 - Other specified parts of pancreasOther specified parts of pancreas
C25.8C25.8 - Overlapping lesion of pancreasOverlapping lesion of pancreas
C25.9C25.9 - Pancreas, NOSPancreas, NOS
C26C26 - OTHER AND ILL-DEFINED DIGESTIVE ORGANSOTHER AND ILL
C26.0C26.0 - Intestinal tract, NOSIntestinal tract, NOS
C26.8C26.8 - Overlapping lesion of digestive systemOverlapping lesion of digestive system
C26.9C26.9 - Gastrointestinal tract, NOSGastrointestinal tract, NOS
C30C30 - NASAL CAVITY AND MIDDLE EARNASAL CAVITY AND MIDDLE EAR
C30-C39C30-C39 RESPIRATORY SYSTEM AND INTRATHORACIC ORGANSRESPIRATORY SYSTEM AND INTRATHORACIC ORGANS
C30.0C30.0 - Nasal cavity (excludes nose, NOS C76.0)Nasal cavity (excludes nose, NOS C76.0)
C30.1C30.1 - Middle earMiddle ear
C31C31 - ACCESSORY SINUSESACCESSORY SINUSES
C31.0C31.0 - Maxillary sinusMaxillary sinus
C31.1C31.1 - Ethmoid sinusEthmoid sinus
C31.2C31.2 - Frontal sinusFrontal sinus
C31.3C31.3 - Sphenoid sinusSphenoid sinus
C31.8C31.8 - Overlapping lesion of accessory sinusesOverlapping lesion of accessory sinuses
C31.9C31.9 - Accessory sinus, NOSAccessory sinus, NOS
C32C32 - LARYNXLARYNX
C32.0C32.0 - GlottisGlottis
C32.1C32.1 - SupraglottisSupraglottis
C32.2C32.2 - SubglottisSubglottis
C32.3C32.3 - Laryngeal cartilageLaryngeal cartilage
C32.8C32.8 - Overlapping lesion of larynxOverlapping lesion of larynx
C32.9C32.9 - Larynx, NOSLarynx, NOS
C33C33 - TRACHEATRACHEA
C33.9C33.9 - TracheaTrachea
C34C34 - BRONCHUS AND LUNGBRONCHUS AND LUNG
C34.0C34.0 - Main bronchusMain bronchus
C34.1C34.1 - Upper lobe, lungUpper lobe, lung
C34.2C34.2 - Middle lobe, lungMiddle lobe, lung
C34.3C34.3 - Lower lobe, lungLower lobe, lung
C34.8C34.8 - Overlapping lesion of lungOverlapping lesion of lung
C34.9C34.9 - Lung, NOSLung, NOS
C37C37 - THYMUSTHYMUS
C37.9C37.9 - ThymusThymus
C38C38 - HEART, MEDIASTINUM, AND PLEURAHEART, MEDIASTINUM, AND PLEURA
C38.0C38.0 - HeartHeart
C38.1C38.1 - Anterior mediastinumAnterior mediastinum
C38.2C38.2 - Posterior mediastinumPosterior mediastinum
C38.3C38.3 - Mediastinum, NOSMediastinum, NOS
C38.4C38.4 - Pleura, NOSPleura, NOS
C38.8C38.8 - Overlapping lesion of heart, mediastinum, and pleuraOverlapping lesion of heart, mediastinum, and pleura
C39C39 - OTHER AND ILL-DEFINED SITES WITHIN RESPIRATORY SYSTEM AD INTRATHORACIC ORGANSOTHER AND ILL
C39.0C39.0 - Upper respiratory tract, NOSUpper respiratory tract, NOS
C39.8C39.8 - Overlapping lesion of respiratory system and intrathoracic organsOverlapping lesion of respiratory system and intrathoracic organs
C39.9C39.9 - Ill-defined sites within respiratory systemDefined sites within respiratory system
C40C40 - BONES, JOINTS AND ARTICULAR CARTILAGE OF LIMBSBONES, JOINTS AND ARTICULAR CARTILAGE OF LIMBS
C40-C41C40-C41 - BONES, JOINTS AND ARTICULAR CARTILAGEBONES, JOINTS AND ARTICULAR CARTILAGE
C40.0C40.0 - Long bones of upper limb, scapula and associated jointsLong bones of upper limb, scapula and associated joints
C40.1C40.1 - Short bones of upper limb and associated jointsShort bones of upper limb and associated joints
C40.2C40.2 - Long bones of lower limb and associated jointsLong bones of lower limb and associated joints
C40.3C40.3 - Short bones of lower limb and associated jointsShort bones of lower limb and associated joints
C40.8C40.8 - Overlapping lesion of bones, joints and articular cartilage of limbsOverlapping lesion of bones, joints and articular cartilage of limbs
C40.9C40.9 - Bone of limb, NOSBone of limb, NOS
C41C41 - BONES, JOINTS AND ARTICULAR CARTILAGE OF OTHER AND UNSPECIFIED SITESBONES, JOINTS AND ARTICULAR CARTILAGE OF OTHER AND UNSPECIFIED SITES
C41.0C41.0 - Bones of skull and face and associated joints (excludes mandible C41.1)Bones of skull and face and associated joints (excludes mandible C41.1)
C41.1C41.1 - MandibleMandible
C41.2C41.2 - Vertebral column (excludes sacrum and coccyx C41.4)Vertebral column (excludes sacrum and coccyx C41.4)
C41.3C41.3 - Rib, sternum, clavicle and associated jointsRib, sternum, clavicle and associated joints
C41.4C41.4 - Pelvic bones, sacrum, coccyx and associated jointsPelvic bones, sacrum, coccyx and associated joints
C41.8C41.8 - Overlapping lesion of bones, joints and articular cartilageOverlapping lesion of bones, joints and articular cartilage
C41.9C41.9 - Bone, NOSBone, NOS
C42C42 - HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMSHEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS
C42.0C42.0 - BloodBlood
C42.1C42.1 - Bone marrowBone marrow
C42.2C42.2 - SpleenSpleen
C42.3C42.3 - Reticuloendothelial system, NOSReticuloendothelial system, NOS
C42.4C42.4 - Hematopoietic system, NOSHematopoietic system, NOS
C44C44 - SKIN (excludes skin of vulva C51._, skin of penis C60.9, skin of scrotum C63.2)SKIN (excludes skin of vulva C51._, skin of penis C60.9, skin of scrotum C63.2)
C44.0C44.0 - Skin of lip, NOSSkin of lip, NOS
C44.1C44.1 - EyelidEyelid
C44.2C44.2 - External earExternal ear
C44.3C44.3 - Skin of other and unspecified parts of faceSkin of other and unspecified parts of face
C44.4C44.4 - Skin of scalp and neckSkin of scalp and neck
C44.5C44.5 - Skin of trunkSkin of trunk
C44.6C44.6 - Skin of upper limb and shoulderSkin of upper limb and shoulder
C44.7C44.7 - Skin of lower limb and hipSkin of lower limb and hip
C44.8C44.8 - Overlapping lesion of skinOverlapping lesion of skin
C44.9C44.9 - Skin, NOS (excludes skin of labia majora C51.0, skin of vulva C51.9, skin of penis C60.9 and skin of scrotum C63.2)Skin, NOS (excludes skin of labia majora C51.0, skin of vulva C51.9, skin of penis C60.9 and skin of scrotum C63.2)
C47C47 - PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM (includes autonomic nervous system, ganglia, nerve, parasympathetic nervous system, peripheral nerve, spinal nerve, sympathetic nervous system)PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM (includes autonomic nervous system, ganglia, nerve, parasympathetic nervous system, peripheral nerve, spinal nerve, sympathetic nervous system)
C47.0C47.0 - Peripheral nerves and autonomic nervous system of head, face, and neck (excludes peripheral nerves and autonomic nervous system of orbit C69.6)Peripheral nerves and autonomic nervous system of head, face, and neck (excludes peripheral nerves and autonomic nervous system of orbit C69.6)
C47.1C47.1 - Peripheral nerves and autonomic nervous system of upper limb and shoulderPeripheral nerves and autonomic nervous system of upper limb and shoulder
C47.2C47.2 - Peripheral nerves and autonomic nervous system of lower limb and hipPeripheral nerves and autonomic nervous system of lower limb and hip
C47.3C47.3 - Peripheral nerves and autonomic nervous system of thoraxPeripheral nerves and autonomic nervous system of thorax
C47.4C47.4 - Peripheral nerves and autonomic nervous system of abdomenPeripheral nerves and autonomic nervous system of abdomen
C47.5C47.5 - Peripheral nerves and autonomic nervous system of pelvisPeripheral nerves and autonomic nervous system of pelvis
C47.6C47.6 - Peripheral nerves and autonomic nervous system of trunk, NOSPeripheral nerves and autonomic nervous system of trunk, NOS
C47.8C47.8 - Overlapping lesion of peripheral nerves and autonomic nervous systemOverlapping lesion of peripheral nerves and autonomic nervous system
C47.9C47.9 - Autonomic nervous system, NOSAutonomic nervous system, NOS
C48C48 - RETROPERITONEUM AND PERITONEUMRETROPERITONEUM AND PERITONEUM
C48.0C48.0 - RetroperitoneumRetroperitoneum
C48.1C48.1 - Specified parts of peritoneumSpecified parts of peritoneum
C48.2C48.2 - Peritoneum, NOSPeritoneum, NOS
C48.8C48.8 - Overlapping lesion of retroperitoneum and peritoneumOverlapping lesion of retroperitoneum and peritoneum
C49C49 - CONNECTIVE, SUBCUTANEOUS AND OTHER SOFT TISSUCONNECTIVE, SUBCUTANEOUS AND OTHER SOFT TISSU
C49.0C49.0 - Connective, subcutaneous and other soft tissues of head, face, and neck (excludes connective tissue of orbit C69.6 and nasal cartilage C30.0)Connective, subcutaneous and other soft tissues of head, face, and neck (excludes connective tissue of orbit C69.6 and nasal cartilage C30.0)
C49.1C49.1 - Connective, subcutaneous and other soft tissues of upper limb and shoulderConnective, subcutaneous and other soft tissues of upper limb and shoulder
C49.2C49.2 - Connective, subcutaneous and other soft tissues of lower limb and hipConnective, subcutaneous and other soft tissues of lower limb and hip
C49.3C49.3 - Connective, subcutaneous and other soft tissues of thorax (excludes thymus C37.9, heart and mediastinum C38._)Connective, subcutaneous and other soft tissues of thorax (excludes thymus C37.9, heart and mediastinum C38._)
C49.4C49.4 - Connective, subcutaneous and other soft tissues of abdomenConnective, subcutaneous and other soft tissues of abdomen
C49.5C49.5 - Connective, subcutaneous and other soft tissues of pelvisConnective, subcutaneous and other soft tissues of pelvis
C49.6C49.6 - Connective, subcutaneous and other soft tissues of trunk, NOSConnective, subcutaneous and other soft tissues of trunk, NOS
C49.8C49.8 - Overlapping lesion of connective, subcutaneous and other soft tissuesOverlapping lesion of connective, subcutaneous and other soft tissues
C49.9C49.9 - Connective, subcutaneous and other soft tissues, NOSConnective, subcutaneous and other soft tissues, NOS
C50C50 - BREAST (excludes skin of breast C44.5)BREAST (excludes skin of breast C44.5)
C50.0C50.0 - NippleNipple
C50.1C50.1 - Central portion of breastCentral portion of breast
C50.2C50.2 - Upper-inner quadrant of breastUpper inner quadrant of breast
C50.3C50.3 - Lower-inner quadrant of breastLower inner quadrant of breast
C50.4C50.4 - Upper-outer quadrant of breastUpper outer quadrant of breast
C50.5C50.5 - Lower-outer quadrant of breastLower outer quadrant of breast
C50.6C50.6 - Axillary tail of breastAxillary tail of breast
C50.8C50.8 - Overlapping lesion of breastOverlapping lesion of breast
C50.9C50.9 - Breast, NOSBreast, NOS
C51C51 - VULVAVULVA
C51-C58C51-C58 - FEMALE GENITAL ORGANSFEMALE GENITAL ORGANS
C51.0C51.0 - Labium majusLabium majus
C51.1C51.1 - Labium minusLabium minus
C51.2C51.2 - ClitorisClitoris
C51.8C51.8 - Overlapping lesion of vulvaOverlapping lesion of vulva
C51.9C51.9 - Vulva, NOSVulva, NOS
C52C52 - VAGINAVAGINA
C52.9C52.9 - Vagina, NOSVagina, NOS
C53C53 - CERVIX UTERICERVIX UTERI
C53.0C53.0 - EndocervixEndocervix
C53.1C53.1 - ExocervixExocervix
C53.8C53.8 - Overlapping lesion of cervix uteriOverlapping lesion of cervix uteri
C53.9C53.9 - Cervix uteriCervix uteri
C54C54 - CORPUS UTERICORPUS UTERI
C54.0C54.0 - Isthmus uteriIsthmus uteri
C54.1C54.1 - EndometriumEndometrium
C54.2C54.2 - MyometriumMyometrium
C54.3C54.3 - Fundus uteriFundus uteri
C54.8C54.8 - Overlapping lesion of corpus uteriOverlapping lesion of corpus uteri
C54.9C54.9 - Corpus uteriCorpus uteri
C55C55 - UTERUS, NOSUTERUS, NOS
C55.9C55.9 - Uterus, NOSUterus, NOS
C56C56 - OVARYOVARY
C56.9C56.9 - OvaryOvary
C57C57 - OTHER AND UNSPECIFIED FEMALE GENITAL ORGANSOTHER AND UNSPECIFIED FEMALE GENITAL ORGANS
C57.0C57.0 - Fallopian tubeFallopian tube
C57.1C57.1 - Broad ligamentBroad ligament
C57.2C57.2 - Round ligamentRound ligament
C57.3C57.3 - ParametriumParametrium
C57.4C57.4 - Uterine adnexaUterine adnexa
C57.7C57.7 - Other specified parts of female genital organsOther specified parts of female genital organs
C57.8C57.8 - Overlapping lesion of female genital organsOverlapping lesion of female genital organs
C57.9C57.9 - Female genital tract, NOSFemale genital tract, NOS
C58C58 - PLACENTAPLACENTA
C58.9C58.9 - PlacentaPlacenta
C60C60 - PENISPENIS
C60-C63C60-C63 - MALE GENITAL ORGANSMALE GENITAL ORGANS
C60.0C60.0 - PrepucePrepuce
C60.1C60.1 - Glans penisGlans penis
C60.2C60.2 - Body of penisBody of penis
C60.8C60.8 - Overlapping lesion of penisOverlapping lesion of penis
C60.9C60.9 - Penis, NOSPenis, NOS
C61C61 - PROSTATE GLANDPROSTATE GLAND
C61.9C61.9 - Prostate glandProstate gland
C62C62 - TESTISTESTIS
C62.0C62.0 - Undescended testis (site of neoplasm)Undescended testis (site of neoplasm)
C62.1C62.1 - Descended testisDescended testis
C62.9C62.9 - Testis, NOSTestis, NOS
C63C63 - OTHER AND UNSPECIFIED MALE GENITAL ORGANSOTHER AND UNSPECIFIED MALE GENITAL ORGANS
C63.0C63.0 - EpididymisEpididymis
C63.1C63.1 - Spermatic cordSpermatic cord
C63.2C63.2 - Scrotum, NOSScrotum, NOS
C63.7C63.7 - Other specified parts of male genital organsOther specified parts of male genital organs
C63.8C63.8 - Overlapping lesion of male genital organsOverlapping lesion of male genital organs
C63.9C63.9 - Male genital organs, NOSMale genital organs, NOS
C64C64 - KIDNEYKIDNEY
C64-C68C64-C68 - URINARY TRACTURINARY TRACT
C64.9C64.9 - Kidney, NOSKidney, NOS
C65C65 - RENAL PELVISRENAL PELVIS
C65.9C65.9 - Renal pelvisRenal pelvis
C66C66 - URETERURETER
C66.9C66.9 - UreterUreter
C67C67 - BLADDERBLADDER
C67.0C67.0 - Trigone of bladderTrigone of bladder
C67.1C67.1 - Dome of bladderDome of bladder
C67.2C67.2 - Lateral wall of bladderLateral wall of bladder
C67.3C67.3 - Anterior wall of bladderAnterior wall of bladder
C67.4C67.4 - Posterior wall of bladderPosterior wall of bladder
C67.5C67.5 - Bladder neckBladder neck
C67.6C67.6 - Ureteric orificeUreteric orifice
C67.7C67.7 - UrachusUrachus
C67.8C67.8 - Overlapping lesion of bladderOverlapping lesion of bladder
C67.9C67.9 - Bladder, NOSBladder, NOS
C68C68 - OTHER AND UNSPECIFIED URINARY ORGANSOTHER AND UNSPECIFIED URINARY ORGANS
C68.0C68.0 - UrethraUrethra
C68.1C68.1 - Paraurethral glandParaurethral gland
C68.8C68.8 - Overlapping lesion of urinary organsOverlapping lesion of urinary organs
C68.9C68.9 - Urinary system, NOSUrinary system, NOS
C69C69 - EYE AND ADNEXAEYE AND ADNEXA
C69-C72C69-C72 - EYE, BRAIN AND OTHER PARTS OF CENTRAL NERVOUS SYSTEMEYE, BRAIN AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM
C69.0C69.0 - ConjunctivaConjunctiva
C69.1C69.1 - Cornea, NOSCornea, NOS
C69.2C69.2 - RetinaRetina
C69.3C69.3 - ChoroidChoroid
C69.4C69.4 - Ciliary bodyCiliary body
C69.5C69.5 - Lacrimal glandLacrimal gland
C69.6C69.6 - Orbit, NOSOrbit, NOS
C69.8C69.8 - Overlapping lesion of eye and adnexa (see note page 45)Overlapping lesion of eye and adnexa (see note page 45)
C69.9C69.9 - Eye, NOSEye, NOS
C70C70 - MENINGESMENINGES
C70.0C70.0 - Cerebral meningesCerebral meninges
C70.1C70.1 - Spinal meningesSpinal meninges
C70.9C70.9 - Meninges, NOSMeninges, NOS
C71C71 - BRAINBRAIN
C71.0C71.0 - CerebrumCerebrum
C71.1C71.1 - Frontal lobeFrontal lobe
C71.2C71.2 - Temporal lobeTemporal lobe
C71.3C71.3 - Parietal lobeParietal lobe
C71.4C71.4 - Occipital lobeOccipital lobe
C71.5C71.5 - Ventricle, NOSVentricle, NOS
C71.6C71.6 - Cerebellum, NOSCerebellum, NOS
C71.7C71.7 - Brain stemBrain stem
C71.8C71.8 - Overlapping lesion of brainOverlapping lesion of brain
C71.9C71.9 - Brain, NOSBrain, NOS
C72C72 - SPINAL CORD, CRANIAL NERVES,AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM (excludes peripheral nerves, sympathetic and parasympathetic nerves and ganglia C47)SPINAL CORD, CRANIAL NERVES,AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM (excludes peripheral nerves, sympathetic and parasympathetic nerves and ganglia C47)
C72.0C72.0 - Spinal cordSpinal cord
C72.1C72.1 - Cauda equinaCauda equina
C72.2C72.2 - Olfactory nerveOlfactory nerve
C72.3C72.3 - Optic nerveOptic nerve
C72.4C72.4 - Acoustic nerveAcoustic nerve
C72.5C72.5 - Cranial nerve, NOSCranial nerve, NOS
C72.8C72.8 - Overlapping lesion of brain and central nervous systemOverlapping lesion of brain and central nervous system
C72.9C72.9 - Nervous system, NOSNervous system, NOS
C73C73 - THYROID GLANDTHYROID GLAND
C73-C75C73-C75 - THYROID AND OTHER ENDOCRINE GLANDSTHYROID AND OTHER ENDOCRINE GLANDS
C73.9C73.9 - Thyroid glandThyroid gland
C74C74 - ADRENAL GLANDADRENAL GLAND
C74.0C74.0 - Cortex of adrenal glandCortex of adrenal gland
C74.1C74.1 - Medulla of adrenal glandMedulla of adrenal gland
C74.9C74.9 - Adrenal gland, NOSAdrenal gland, NOS
C75C75 - OTHER ENDOCRINE GLANDS AND RELATED STRUCTURESOTHER ENDOCRINE GLANDS AND RELATED STRUCTURES
C75.0C75.0 - Parathyroid glandParathyroid gland
C75.1C75.1 - Pituitary glandPituitary gland
C75.2C75.2 - Craniopharyngeal ductCraniopharyngeal duct
C75.3C75.3 - Pineal glandPineal gland
C75.4C75.4 - Carotid bodyCarotid body
C75.5C75.5 - Aortic body and other paragangliaAortic body and other paraganglia
C75.8C75.8 - Overlapping lesion of endocrine glands and related structuresOverlapping lesion of endocrine glands and related structures
C75.9C75.9 - Endocrine gland, NOSEndocrine gland, NOS
C76C76 - OTHER AND ILL-DEFINED SITESOTHER AND ILL
C76.0C76.0 - Head, face or neck, NOSHead, face or neck, NOS
C76.1C76.1 - Thorax, NOSThorax, NOS
C76.2C76.2 - Abdomen, NOSAbdomen, NOS
C76.3C76.3 - Pelvis, NOSPelvis, NOS
C76.4C76.4 - Upper limb, NOSUpper limb, NOS
C76.5C76.5 - Lower limb, NOSLower limb, NOS
C76.7C76.7 - Other ill-defined sitesOther ill
C76.8C76.8 - Overlapping lesion of ill-defined sitesOverlapping lesion of ill
C77C77 - LYMPH NODESLYMPH NODES
C77.0C77.0 - Lymph nodes of head, face and neckLymph nodes of head, face and neck
C77.1C77.1 - Intrathoracic lymph nodesIntrathoracic lymph nodes
C77.2C77.2 - Intra-abdominal lymph nodesIntra abdominal lymph nodes
C77.3C77.3 - Lymph nodes of axilla or armLymph nodes of axilla or arm
C77.4C77.4 - Lymph nodes of inguinal region or legLymph nodes of inguinal region or leg
C77.5C77.5 - Pelvic lymph nodesPelvic lymph nodes
C77.8C77.8 - Lymph nodes of multiple regionsLymph nodes of multiple regions
C77.9C77.9 - Lymph node, NOSLymph node, NOS
C80C80 - UNKNOWN PRIMARY SITEUNKNOWN PRIMARY SITE
C80.9C80.9 - Unknown primary siteUnknown primary site
Conditional Response QuestionsThere are business rules to indicate situations under which these elements should be used on a case report form.
If Other Assessment Method, SpecifyDisease Response Evaluation Method Other Specify Text38555611.0CHARACTER
Optional Response QuestionsThere is no requirement for inclusion of these elements on the case report form. If the design and scientific questions posed in the study dictate the need to collect this type of data, these elements should be included.
Response Evaluation Period Start DateDisease Response Evaluation Period Start Date38211541.0DATEmm/dd/yyyy
Response Evaluation Period End DateDisease Response Evaluation Period End Date38211551.0DATEmm/dd/yyyy
Protocol TimepointDisease Response Evaluation Study Protocol Timepoint Name38211571.0CHARACTER
Completion of Therapy (per protocol)Complete Clinical Study Therapeutic ProcedureTo possess every necessary or normal part or component or step; having come or been brought to a conclusion.: Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research. : An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.
ConsolidationConsolidation TherapyTreatment that is given after cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. It may include radiation therapy, a stem cell transplant, or treatment with drugs that kill cancer cells.
CourseCourseA period of protocol-prescribed activity or intervention.
CycleCycleAn event or sequence of events that constitute round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.
DayDayThe time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours.
Days Off TreatmentDay Off TreatmentThe time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day. : When a patient is not receiving therapy they are considered off treatment. In clinical trials, a dosing schedule may require a patient to stop medication for a period of time, then resume, such as 28 days on and 7 days off.
InductionNeoadjuvant TherapyTreatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy. It is a type of induction therapy.
MaintenanceMaintenance TherapyContinuation of treatment for an extended period of time to prevent relapse.
MonthMonthOne of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks.
Months Off TreatmentMonth Off Treatment Month Off TreatmentOne of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks.: When a patient is not receiving therapy they are considered off treatment. In clinical trials, a dosing schedule may require a patient to stop medication for a period of time, then resume, such as 28 days on and 7 days off.: One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks.: When a patient is not receiving therapy they are considered off treatment. In clinical trials, a dosing schedule may require a patient to stop medication for a period of time, then resume, such as 28 days on and 7 days off.
Off Treatment (premature)Off TreatmentWhen a patient is not receiving therapy they are considered off treatment. In clinical trials, a dosing schedule may require a patient to stop medication for a period of time, then resume, such as 28 days on and 7 days off.
Recurrent DiseaseRecurrent DiseaseThe return of a disease after a period of remission.
YearYearThe period of time that it takes for Earth to make a complete revolution around the sun; a period of time containing 365 days.
Years Off TreatmentYear Off TreatmentThe period of time that it takes for Earth to make a complete revolution around the sun; a period of time containing 365 days.: When a patient is not receiving therapy they are considered off treatment. In clinical trials, a dosing schedule may require a patient to stop medication for a period of time, then resume, such as 28 days on and 7 days off.
Morphologic Status (AML/MDS)Acute Myeloid Leukemia Or Myelodysplastic Syndrome Morphologic Response Status38555621.0CHARACTER
Complete Remission (CR)Complete RemissionThe disappearance of all signs of cancer in response to treatment.
Leukemic TransformationLeukemic Cell TransformationMalignant hematopoietic cell originating in the clonal proliferation of myeloid or lymphoid precursor that undergoes an aberrant and poorly regulated process of organogenesis resulted in arrested maturation and cell capacity for unlimited self-renewal.: The conversion of a cell from a normal phenotype, which undergoes a limited number of mitotic divisions, into an aberrant phenotype that is immortal and divides indefinitely. Transformed cells no longer retain cell-cycle checkpoints and may ultimately become malignant cancer cells via additional genetic mutations, or damaging environmental events.
Morphologic Complete Response with Incomplete Blood Count Recovery (CRi)Complete Response with Incomplete Bone Marrow RecoveryThe disappearance of all signs of cancer in response to treatment accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.
Morphologic RelapseMorphologic Finding Recurrent DiseaseA light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.: The return of a disease after a period of remission.
Not AssessedNegation AssessmentAn operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.
Not EvaluableUnevaluableUnable to be evaluated.
Partial Remission (PR)Partial RemissionA finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.
Morphologic Status (Acute Leukemia/CML)Acute Leukemia Or Chronic Myelogenous Leukemia Morphologic Response Status38555631.0CHARACTER
Complete Remission (CR)Complete RemissionThe disappearance of all signs of cancer in response to treatment.
Morphologic Complete Remission with Incomplete Blood Count Recovery (CRi)Complete Response with Incomplete Bone Marrow RecoveryThe disappearance of all signs of cancer in response to treatment accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.
Morphologic Leukemia Free StateMorphologic Finding Leukemia Absent StateA light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.: Not existing in a specified place at a specified time.: State; the way something is with respect to its main attributes.
Morphologic RelapseMorphologic Finding Recurrent DiseaseA light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.: The return of a disease after a period of remission.
Not AssessedNegation AssessmentAn operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.
Not EvaluableUnevaluableUnable to be evaluated.
Partial Remission (PR)Partial RemissionA finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.
Cytogenetic Status (AML/MDS)Acute Myeloid Leukemia Or Myelodysplastic Syndrome Cytogenetic Response Status38555641.0CHARACTER
Cytogenetic Complete Remission (CRc)Cytogenetic Analysis Complete RemissionTechniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The disappearance of all signs of cancer in response to treatment.
Cytogenetic ProgressionCytogenetic Analysis Disease ProgressionTechniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: Cancer that continues to grow or spread.
Cytogenetic RelapseCytogenetic Analysis Recurrent DiseaseTechniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The return of a disease after a period of remission.
Not AssessedNegation AssessmentAn operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.
Not EvaluableUnevaluableUnable to be evaluated.
Cytogenetic Status (Acute Leukemia/CML (BC))Acute Leukemia Or Blast Phase Chronic Myelogenous Leukemia Cytogenetic Response Status38555651.0CHARACTER
Cytogenetic Complete Remission (CRc)Cytogenetic Analysis Complete RemissionTechniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The disappearance of all signs of cancer in response to treatment.
Cytogenetic RelapseCytogenetic Analysis Recurrent DiseaseTechniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The return of a disease after a period of remission.
Not AssessedNegation AssessmentAn operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.
Not EvaluableUnevaluableUnable to be evaluated.
Cytogenetic Status (CML (AP))Accelerated Phase Chronic Myelogenous Leukemia Cytogenetic Response Status38555711.0CHARACTER
Complete Cytogenetic Response (CCyR)Cytogenetic Analysis Complete RemissionTechniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The disappearance of all signs of cancer in response to treatment.
Major Cytogenetic Response (MCyR)Major Cytogenetic Analysis RemissionGreater or bigger in amount, extent, or size.: Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: An abatement in intensity or degree (as in the manifestations of a disease).
Minimal Cytogenetic ResponseMinimum Cytogenetic Analysis RemissionThe smallest possible quantity.: Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: An abatement in intensity or degree (as in the manifestations of a disease).
Minor Cytogenetic Response (MiCyR)Minor Cytogenetic Analysis RemissionLesser or smaller in amount, extent, or size.: Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: An abatement in intensity or degree (as in the manifestations of a disease).
No Cytogenetic ResponseNo Cytogenetic Analysis RemissionAn operation in which a term denies or inverts the meaning of another term or construction.: Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: An abatement in intensity or degree (as in the manifestations of a disease).
Not AssessedNegation AssessmentAn operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.
Not EvaluableUnevaluableUnable to be evaluated.
Partial Cytogenetic Response (PCyR)Cytogenetic Analysis Partial RemissionTechniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.
Molecular StatusLeukemia Molecular Response Status38555721.0CHARACTER
Molecular Complete Remission (CRm)Molecular Analysis Complete RemissionTechniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).: The disappearance of all signs of cancer in response to treatment.
Molecular RelapseMolecular Analysis Recurrent DiseaseTechniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).: The return of a disease after a period of remission.
Not AssessedNegation AssessmentAn operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.
Not EvaluableUnevaluableUnable to be evaluated.
Other StatusDisease Response Other Status38555731.0CHARACTER
AplasiaBone Marrow AplasiaBone Marrow Aplasia
Indeterminate CauseIndeterminateCannot distinguish between two or more possible values in the current context.
Resistant DiseaseRefractory CarcinomaCancer that does not respond to treatment. The cancer may be resistant at the beginning of treatment, or it may become resistant during treatment.
PSA StatusProstate Carcinoma Response Current PSA Measurement Change Status38555741.0CHARACTER
Not AssessedNegation AssessmentAn operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.
Not EvaluableUnevaluableUnable to be evaluated.
PSA-N (CR)Prostate Specific Antigen Measurement Negative Finding Complete RemissionThe determination of the prostate specific antigen present in a sample.: A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.: The disappearance of all signs of cancer in response to treatment.
PSA-NR (Borderline Stable)Prostate Specific Antigen Measurement Borderline Stable DiseaseThe determination of the prostate specific antigen present in a sample.: Straddling the dividing line between two categories.: Cancer that is neither decreasing nor increasing in extent or severity.
PSA-PR (PR)Prostate Specific Antigen Measurement Partial RemissionThe determination of the prostate specific antigen present in a sample.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.
PSA-ProgressionProstate Specific Antigen Measurement Tumor ProgressionThe determination of the prostate specific antigen present in a sample.: The molecular steps that continually advance a cancer or cancer cell into a more malignant and aggressive phenotype.
PSA-StableProstate Specific Antigen Measurement Stable DiseaseThe determination of the prostate specific antigen present in a sample.: Cancer that is neither decreasing nor increasing in extent or severity.
Unconfirmed PSA CRProstate Specific Antigen Measurement Unconfirmed Complete RemissionThe determination of the prostate specific antigen present in a sample.: An operation in which a term denies or inverts the meaning of another term or construction.: Confirmed; having been established or verified.: The disappearance of all signs of cancer in response to treatment.
Unconfirmed PSA PRProstate Specific Antigen Measurement Unconfirmed Partial RemissionThe determination of the prostate specific antigen present in a sample.: An operation in which a term denies or inverts the meaning of another term or construction.: Confirmed; having been established or verified.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.
Hematologic Improvement Response (AML/MDS) - Select all that applyAcute Myeloid Leukemia Or Myelodysplastic Syndrome Hematologic Improvement Response Status38555751.0CHARACTER
Erythroid ResponseErythroid Response1) Reddish in color. 2) relating to erythrocytes or their precursors.: The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.
Neutrophil ResponseNeutrophil ResponseGranular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.: The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.
Not AssessedNegation AssessmentAn operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.
Not EvaluableUnevaluableUnable to be evaluated.
Platelet ResponsePlatelet ResponseAn irregular, disc-shaped element in the blood that assists in blood clotting. Platelets are not blood cells, they are fragments of large bone marrow cells called megakaryocytes: The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.
Progression or Relapse after Hematologic ImprovementDisease Progression Or Recurrent Disease Post Hematologic ImprovementCancer that continues to grow or spread.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: The return of a disease after a period of remission.: Happening at a time subsequent to a reference time; later in time or order.: Pertaining to or related to the blood and blood-forming organs.: A condition superior to an earlier condition.
Hematologic Response (CML(AP))Accelerated Phase Chronic Myelogenous Leukemia Hematologic Response Status38555761.0CHARACTER
Complete Hematologic Response (CHR)Hematologic Complete RemissionPertaining to or related to the blood and blood-forming organs.: The disappearance of all signs of cancer in response to treatment. This does not always mean the cancer has been cured.
Major Hematologic Response (MaHR)Major Hematologic ResponseGreater or bigger in amount, extent, or size.: Pertaining to or related to the blood and blood-forming organs.: The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.
Minor Hematologic Response (MiHR)Minor Hematologic ResponseLesser or smaller in amount, extent, or size.: Pertaining to or related to the blood and blood-forming organs.: The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.
No Evidence of Leukemia (NEL)Negation Evidence LeukemiaAn operation in which a term denies or inverts the meaning of another term or construction.: Knowledge on which to base belief.: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.
Not AssessedNegation AssessmentAn operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.
Not EvaluableUnevaluableUnable to be evaluated.
Current ResponseDisease Response Current Status38555771.0CHARACTER
Borderline Stable DiseaseBorderline Stable DiseaseStraddling the dividing line between two categories.: Cancer that is neither decreasing nor increasing in extent or severity.
Complete Remission (CR)Complete RemissionThe disappearance of all signs of cancer in response to treatment.
No Evidence of Disease (NED)No Evidence of DiseaseDiagnostic tests fail to detect presence of disease.
Not EvaluableUnevaluableUnable to be evaluated.
Partial Remission (PR)Partial RemissionA finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.
Progressive Disease (PD)PDCancer that is increasing in scope or severity.
Stable Disease (SD)Stable DiseaseCancer that is neither decreasing nor increasing in extent or severity.
Unconfirmed Complete RemissionNot Confirmed Complete RemissionAn operation in which a term denies or inverts the meaning of another term or construction.: Having been established or verified.: The disappearance of all signs of cancer in response to treatment.
Unconfirmed Partial RemissionNot Confirmed Partial RemissionAn operation in which a term denies or inverts the meaning of another term or construction.: Having been established or verified.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.
irRC ResponseTumor Immune Response Type35532721.0CHARACTER
irCRImmune-related Complete ResponseDisappearance of all lesions in two consecutive observations not less than 4 weeks apart
irPDImmune-related Progressive DiseaseAt least 25% increase in tumor burden compared with nadir (at any single time point) in two consecutive observations at least 4 weeks apart
irPRImmune-related Partial Response>= 50% decrease in tumor burden compared with baseline in two observations at least 4 weeks apart
irSDImmune-related Stable Disease50% decrease in tumor burden compared with baseline cannot be established nor 25% increase compared with nadir
New, measurable lesions (>=5x5 mm)New measurable lesions (>= 5x5 mm)Incorporated into tumor burden
New, nonmeasurable lesions (<5x5 mm)New nonmeasurable lesions (< 5x5 mm)Do not define progression (but preclude irCR)
Non-index lesionsNon-index lesionsContribute to defining irCR (complete disappearance required)
Not EvaluableUnevaluableUnable to be evaluated.
Current Response (MM)Multiple Myeloma Current Response Status38555781.0CHARACTER
Complete Response (CR)Complete Response of Multiple Myeloma or Plasma Cell LeukemiaComplete response of multiple myeloma or plasma cell leukemia is characterized by negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and 5% or less plasma cells in the bone marrow (confirmation with repeat bone marrow biopsy not needed). Complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy complete response requirements.
Not EvaluableUnevaluableUnable to be evaluated.
Partial Response (PR)Partial Response of Multiple Myeloma or Plasma Cell LeukemiaPartial response of multiple myeloma or plasma cell leukemia is characterized by a 50% or greater reduction in serum M-protein, and reduction in 24-hour urinary M-protein by 90% or more or to less than 200 mg/24 hours. If the serum and urine M-protein are unmeasurable (i.e., do not meet any of the following criteria: 1. serum M-protein at least 1 g/dL; 2. urine M-protein at least 200 mg/24 hours; 3. serum free light chain assay shows involved level at least 10 mg/dL, provided serum free light chain ratio is abnormal), a 50% or more decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, a 50% or more reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was 30% or more. In addition to the above listed criteria, a 50% or more reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. Partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy partial response requirements.
ProgressionProgression of Multiple Myeloma or Plasma Cell LeukemiaProgression of multiple myeloma or plasma cell leukemia requires any one or more of the following: Increase of 25% or more from baseline in: serum M-component and/or absolute increase 0.5 g/dL or more (for progressive disease, serum M-component increases of 1 g/dL or more are sufficient to define relapse if the starting M component is 5 g/dL or more); urine M-component and/or absolute increase 200 mg. or more 24 hours; for recipients without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase 10 mg/dL or more); bone marrow plasma cell percentage (absolute percentage 10% or more) (relapse from complete response has a 5% cutoff vs. 10% for other categories of relapse); definite development of new bone lesions or soft tissue plasmacytomas, or definite increase in the size of any existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium more than11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder. Progression of disease requires two consecutive assessments made at any time before classification as disease progression, and/or the institution of any new therapy.
Stable Disease (SD)Stable Multiple Myeloma or Plasma Cell LeukemiaStable multiple myeloma or plasma cell leukemia is characterized by not meeting the criteria for complete response, very good partial response, partial response or progression of disease. Stable disease requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stable disease requirements.
Stringent Complete Response (sCR)Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell LeukemiaStringent complete response (sCR) of multiple myeloma or plasma cell leukemia is characterized by complete response plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence (confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the kappa/lamda ratio. An abnormal kappa/lambda ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an abnormal clone is kappa/lambda of > 4:1 or < 1:2.). Stringent complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stringent complete response requirements.
Very Good Partial Response (VGPR)Very Good Partial Response of Multiple Myeloma or Plasma Cell LeukemiaVery good partial response of multiple myeloma or plasma cell leukemia is characterized by serum and urine M-protein detectable by immunofixation but not on electrophoresis, or at least 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours. Very good partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy very good partial response requirements.
Current Response (AML/ALL)Acute Myeloid Leukemia Or Acute Lymphoblastic Leukemia Current Response Status38555791.0CHARACTER
Bone Marrow CR (CRm)Bone Marrow Complete RemissionThe tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes. : The disappearance of all signs of cancer in response to treatment.
Complete Cytogenetic Remission (CCyR)Cytogenetic Analysis Complete RemissionTechniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The disappearance of all signs of cancer in response to treatment.
Complete Remission with Incomplete Blood Count Recovery (CRi)Complete Response with Incomplete Bone Marrow RecoveryThe disappearance of all signs of cancer in response to treatment accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.
Complete Remission with Incomplete Platelet RecoveryComplete Remission With Incomplete Platelet RecoveryThe disappearance of all signs of cancer in response to treatment.: Used to indicate the presence of something or someone.: Not whole; lacking some necessary part or detail; unfinished.: An irregular, disc-shaped element in the blood that assists in blood clotting. Platelets are not blood cells, they are fragments of large bone marrow cells called megakaryocytes: A getting back or regaining.
Complete Remission with MRDComplete Remission With Minimal Residual DiseaseThe disappearance of all signs of cancer in response to treatment.: Used to indicate the presence of something or someone.: remainder of a tumor or a neoplasm/cancer after primary, potentially curative therapy.
Complete Remission without MRDComplete Remission Without Minimal Residual DiseaseThe disappearance of all signs of cancer in response to treatment.: Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): remainder of a tumor or a neoplasm/cancer after primary, potentially curative therapy.
Cytogenetic ResponseCytogenetic Analysis ResponseTechniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.
Disease ProgressionDisease ProgressionCancer that continues to grow or spread.
FailureTherapeutic Procedure FailureAn action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: A lack of occurrence or performance.
Minimum Residual Disease (MDR)Minimal Residual Diseaseremainder of a tumor or a neoplasm/cancer after primary, potentially curative therapy.
Not EvaluableUnevaluableUnable to be evaluated.
Partial Remission (PR)Partial RemissionA finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.
Progressive Disease (PD)PDCancer that is increasing in scope or severity.
Recurrent DiseaseRecurrent DiseaseThe return of a disease after a period of remission.
Relapse after CR or PRRecurrent Disease Post Complete Remission Or Partial RemissionThe return of a disease after a period of remission.: Happening at a time subsequent to a reference time; later in time or order.: The disappearance of all signs of cancer in response to treatment.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.
Treatment Failure - Death from Indeterminate CauseTreatment Failure Death from Indeterminate CauseThe cessation of life.: Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument.: Cannot distinguish between two or more possible values in the current context.: An explanation of the cause of some phenomenon or action.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: A lack of occurrence or performance.
Treatment Failure - Death in AplasiaTreatment Failure Death Due To AplasiaThe cessation of life.: Caused by or resulting from.: A condition in which the bone marrow is unable to produce blood cells.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: A lack of occurrence or performance.
Treatment Failure - Resistant DiseaseTreatment Failure Resistant DiseaseCancer that does not respond to treatment. The cancer may be resistant at the beginning of treatment, or it may become resistant during treatment.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: A lack of occurrence or performance.
Current Response (APL - M3 AML)Acute Promyelocytic Leukemia Current Response Status38555801.0CHARACTER
Cytogenetic Complete Remission (CRc)Cytogenetic Analysis Complete RemissionTechniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The disappearance of all signs of cancer in response to treatment.
Molecular Complete Remission (CRm)Molecular Analysis Complete RemissionTechniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).: The disappearance of all signs of cancer in response to treatment.
Molecular RelapseMolecular Analysis Recurrent DiseaseTechniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).: The return of a disease after a period of remission.
Morphologic Complete RemissionMorphologic Finding Complete RemissionA light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.: The disappearance of all signs of cancer in response to treatment.
Morphologic Complete Remission with Incomplete Blood Count Recovery (CRi)Complete Response with Incomplete Bone Marrow RecoveryThe disappearance of all signs of cancer in response to treatment accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.
Not EvaluableUnevaluableUnable to be evaluated.
Treatment Failure - Resistant DiseaseTreatment Failure Resistant DiseaseCancer that does not respond to treatment. The cancer may be resistant at the beginning of treatment, or it may become resistant during treatment.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: A lack of occurrence or performance.
Current Response (CML)Chronic Myelogenous Leukemia Current Response Status38555811.0CHARACTER
Complete Cytogenetic Remission (CCyR)Cytogenetic Analysis Complete RemissionTechniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The disappearance of all signs of cancer in response to treatment.
Complete Hematologic Remission (CHR)Hematologic Complete RemissionPertaining to or related to the blood and blood-forming organs.: The disappearance of all signs of cancer in response to treatment. This does not always mean the cancer has been cured.
Cytogenetic ProgressionCytogenetic Analysis Disease ProgressionTechniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: Cancer that continues to grow or spread.
Cytogenetic RelapseCytogenetic Analysis Recurrent DiseaseTechniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The return of a disease after a period of remission.
Emergence of an Acquired ABL Kinase Domain MutationEmergence of an Acquired ABL KinaseEmergence of an Acquired ABL Kinase
Karyotypic EvolutionKaryotype EvolutionKaryotype; the appearance of the chromosomal makeup of a somatic cell in an individual or species, including the number and arrangement and size and structure of the chromosomes.: The process of cumulative change over successive generations through which organisms acquire their distinguishing morphological and physiological characteristics.
Major Molecular Remission (MMR)Major Molecular Analysis ResponseGreater or bigger in amount, extent, or size.: Techniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).: An abatement in intensity or degree (as in the manifestations of a disease).
Not EvaluableUnevaluableUnable to be evaluated.
Current Response (CLL)Chronic Lymphocytic Leukemia Current Response Status38555821.0CHARACTER
Complete Clinical Remission (CCR)Clinical Assessment Tool Complete RemissionAny one of several evaluation/assessment tools used to ascertain a patient's condition or diagnosis.: The disappearance of all signs of cancer in response to treatment.
Complete Remission (CR)Complete RemissionThe disappearance of all signs of cancer in response to treatment.
Nodular Partial Response (nPR)Nodular Partial ResponseRemission with remaining lymphoid nodules reflecting residual disease.
Not AssessedNegation AssessmentAn operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.
Not EvaluableUnevaluableUnable to be evaluated.
Partial Remission (PR)Partial RemissionA finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.
Progressive Disease (PD)PDCancer that is increasing in scope or severity.
Stable Disease (SD)Stable DiseaseCancer that is neither decreasing nor increasing in extent or severity.
Current Response (MDS)Myelodysplastic Syndrome Current Response Status38555831.0CHARACTER
Bone Marrow CR (CRm)Bone Marrow Complete RemissionThe tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes. : The disappearance of all signs of cancer in response to treatment.
Complete Remission (CR)Complete RemissionThe disappearance of all signs of cancer in response to treatment.
Disease TransformationMyelodysplastic Syndrome TransformationA clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001): The conversion of a cell from a normal phenotype, which undergoes a limited number of mitotic divisions, into an aberrant phenotype that is immortal and divides indefinitely. Transformed cells no longer retain cell-cycle checkpoints and may ultimately become malignant cancer cells via additional genetic mutations, or damaging environmental events.
FailureTherapeutic Procedure FailureAn action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: A lack of occurrence or performance.
Hematologic Improvement (HI)Hematologic ImprovementPertaining to or related to the blood and blood-forming organs.: A condition superior to an earlier condition.
Not AssessedNegation AssessmentAn operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.
Not EvaluableUnevaluableUnable to be evaluated.
Partial Remission (PR)Partial RemissionA finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.
Progressive Disease (PD)PDCancer that is increasing in scope or severity.
Relapse after CR or PRRecurrent Disease Post Complete Remission Or Partial RemissionThe return of a disease after a period of remission.: Happening at a time subsequent to a reference time; later in time or order.: The disappearance of all signs of cancer in response to treatment.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.
Stable Disease (SD)Stable DiseaseCancer that is neither decreasing nor increasing in extent or severity.
Current Response (Lymphoma)Lymphoma Current Response Status38555841.0CHARACTER
Complete Remission (CR)Complete RemissionThe disappearance of all signs of cancer in response to treatment.
Not AssessedNegation AssessmentAn operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.
Not EvaluableUnevaluableUnable to be evaluated.
Partial Remission (PR)Partial RemissionA finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.
Progressive Disease (PD)PDCancer that is increasing in scope or severity.
Stable Disease (SD)Stable DiseaseCancer that is neither decreasing nor increasing in extent or severity.
Can treatment be considered having failed?Leukemia Treatment Failure Indicator38555851.0CHARACTER
NoNoThe non-affirmative response to a question.
Not EvaluableUnevaluableUnable to be evaluated.
YesYesThe affirmative response to a question or activity.
If considered treatment failure, provide reasonLeukemia Treatment Failure Reason Type38555861.0CHARACTER
AplasiaBone Marrow AplasiaBone Marrow Aplasia
Death of Patient with Evidence of Persistent LeukemiaDeath With Evidence Persistent LeukemiaThe cessation of life.: Used to indicate the presence of something or someone.: Knowledge on which to base belief.: A disease that does not go to remission despite treatment.: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.
Death of Patient without Evidence of Persistent LeukemiaDeath Without Evidence Persistent LeukemiaThe cessation of life.: Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): Knowledge on which to base belief.: A disease that does not go to remission despite treatment.: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.
Indeterminate CauseIndeterminateCannot distinguish between two or more possible values in the current context.
Molecular or Cytogenetic RelapseMolecular Analysis Or Cytogenetic Analysis Recurrent DiseaseTechniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The return of a disease after a period of remission.
Morphologic RelapseMorphologic Finding Recurrent DiseaseA light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.: The return of a disease after a period of remission.
Resistant DiseaseRefractory CarcinomaCancer that does not respond to treatment. The cancer may be resistant at the beginning of treatment, or it may become resistant during treatment.
Did study subject have PSA Progression?PSA Progression Indicator38555921.0CHARACTER
NoNoThe non-affirmative response to a question.
YesYesThe affirmative response to a question or activity.
CommentsResearch Comments Text7975.0CHARACTER